Larimar Therapeutics Inc. (LRMR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Larimar Therapeutics Inc. (NASDAQ: LRMR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.47 (-7.49% 1D, market cap $256.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LRMR ranks #629 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LRMR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, LRMR leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).
Per LRMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374690), Larimar Therapeutics Inc. generated $0 in revenue, -$165.7M in net income, and -$113.3M in free cash flow against $145.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While LRMR currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.15) and Max Pain ($2.59) forces dealer call-delta covering toward $6.74.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Larimar Therapeutics Inc. (LRMR) dropped -7.49% to $2.47, trading at 12% of its 52-week range ($1.91 – $6.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance UK report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LRMR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LRMR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Larimar Therapeutics Inc. (LRMR) ranks #629 by composite RQD confidence (34/100, grade E) and #535 by equity capitalization ($256.6M). Within this direct 5-issuer industry benchmark cohort, LRMR leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. LRMR currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LRMR
ACTIVE
Larimar Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -7.49% | $256.6M | Benchmark Subject |
| BCYC Bicycle Therapeutics plc | E | 20/100 | — | — | -35.0% | -4.19% | $256.5M | /bcyc-vs-lrmr → |
| GLSI Greenwich LifeSciences Inc. | E | 31/100 | — | — | -35.0% | -8.37% | $255.5M | /glsi-vs-lrmr → |
| AMRN Amarin Corporation plc | E | 32/100 | — | 56.6% | -12.2% | -4.91% | $249.9M | /amrn-vs-lrmr → |
| ABEO Abeona Therapeutics Inc. | E | 23/100 | — | 73.7% | -35.0% | -4.61% | $248.8M | /abeo-vs-lrmr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Larimar Therapeutics Inc. (LRMR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$165.7M, operating cash flow of -$113.2M, and free cash flow of -$113.3M (-59.0% YoY). On the balance sheet, LRMR closed FY2025 with $145.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$165.7M | -$113.2M | -$113.3M | $145.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$80.6M | -$70.8M | -$71.3M | $200.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$36.9M | -$33.5M | -$33.5M | — | — |
As of 2026-11-03, Larimar Therapeutics Inc. (NASDAQ: LRMR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.47 (-7.49% 1D, market cap $256.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LRMR ranks #629 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LRMR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, LRMR leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).
Per LRMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374690), Larimar Therapeutics Inc. generated $0 in revenue, -$165.7M in net income, and -$113.3M in free cash flow against $145.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LRMR last traded at $2.47 (-7.49% on volume of 781,292 shares), positioning the stock -21.59% below its 50-day simple moving average ($3.15) and -35.00% below its 200-day simple moving average ($3.80). Across its 52-week range of $1.91 to $6.42, LRMR sits at the 12.4% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.16 to $2.78).
Why LRMR Stock dropped -7.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, LRMR scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
Taken together, the rating frames LRMR as a high-risk, cash-consuming name where the upside case depends on catalysts rather than current fundamentals. The tradeoff a prospective investor faces is an apparent low entry price ($2.67) against negative returns and weak flow scores.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-172.5M | $-165.7M | N/A | $-113.3M | $85.4M | N/A |
| FY 2024 | $0.0M | $-90.9M | $-80.6M | N/A | $-71.3M | $33.2M | N/A |
| FY 2023 | $0.0M | $-41.8M | $-36.9M | N/A | $-33.5M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M in each period, and operating losses widened from $-41.8M (FY 2023) to $-172.5M (FY 2025). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the SEC financials, cash rose to $85.4M in FY 2025, while FCF was $-113.3M, and debt is N/A in the source.
Real-time company headlines, analyst actions, and sector developments for Larimar Therapeutics Inc. (LRMR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance UK report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Larimar Therapeutics Inc. (LRMR) market action, institutional positioning, and fundamental catalysts.
Welcome to the LRMR (Larimar Therapeutics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on LRMR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Larimar Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on LRMR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.67 (52-wk range $1.91 - $6.42), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).